Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Income towards Parent Company (2021 - 2026)

HeartSciences filings provide 6 years of Income towards Parent Company readings, the most recent being -$2.0 million for Q1 2026.

  • On a quarterly basis, Income towards Parent Company rose 21.97% to -$2.0 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$8.5 million, a 1.73% increase, with the full-year FY2025 number at -$8.9 million, down 32.93% from a year prior.
  • Income towards Parent Company hit -$2.0 million in Q1 2026 for HeartSciences, up from -$2.4 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.6 million in Q1 2025.
  • Median Income towards Parent Company over the past 5 years was -$1.9 million (2024), compared with a mean of -$1.9 million.
  • Biggest five-year swings in Income towards Parent Company: tumbled 109.25% in 2022 and later grew 21.97% in 2026.
  • HeartSciences' Income towards Parent Company stood at -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025, then increased by 15.41% to -$2.0 million in 2026.
  • The last three reported values for Income towards Parent Company were -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025) per Business Quant data.